Nutramedic &Cosmetics
®
Actiful Reduces Methylglyoxal, an Important Marker for Healthy Ageing Actiful® is used globally by leading supplement brands in a vast array of products supporting an active lifestyle and healthy aging. A randomized double blinded crossover study showed the potential of Actiful® as a dietary modulator against advanced glycation end-products (AGEs).
A
randomized double blinded crossover study performed by Maastricht University, showed the potential of Actiful® as a dietary modula tor against advanced glycation end-products (AGEs). AGEs are associated with various age-related chronic diseases. After a 4-week period of Actiful® consump tion in healthy elderly subjects, plasma levels of meth ylglyoxal (MGO) decreased significantly by 9.8% (p = 0.042). These new clinical results highlight Actiful®’s potential to mitigate age-related diseases like dia betes, vascular dysfunction and neurodegeneration.
Actiful®: an energy-boosting ingredient developed by BioActor
Actiful® is a clinically validated blend of Citrus si nensis (sweet orange) and Punica granatum (pomegra nate) extracts. These plants are abundant in bioac tive polyphenolic components, mainly flavonoids1,2. Actiful® has a dual mode of action: by increasing syn thesis of nitric oxide and by improving ATP produc tion through an increased mitochondrial respiration efficiency3. In the first clinical study, Actiful® demon strated to improve energy, mood and antioxidant sta tus in healthy elderly individuals. Actiful® is used glo bally by leading supplement brands in a vast array of products supporting an active lifestyle and healthy aging.
The study: A Citrus and Pomegranate Complex Reduces Methylglyoxal in Healthy Elderly Subjects: Secondary Analysis of a Double-Blind Randomized Cross-Over Clinical Trial Introduction This study4 was published in the International Jour nal of Molecular Sciences . It focuses on the evalua tion of additional biomarkers and the effect of Actiful® in reducing the concentrations of reactive α-dicar bonyl compounds (specifically methylglyoxal, glyox al, and 3-deoxyglucosone) in the blood of healthy el derly participants. These α-dicarbonyls are known to contribute to the formation of advanced glycation end-products (AGEs), which are associated with vari ous chronic diseases, including diabetes and cardio vascular diseases5.
Methods Thirty-six healthy elderly subjects were recruited for this double-blind, randomized crossover clinical trial. They received either 700 mg of Actiful® in cap sules, or a placebo for four weeks, with a 4-week washout period in between. Blood samples were collected during the test day to measure α-Dicarbonyls in plasma. This was achie ved via ultra-performance liquid chromatography tandem mass spectrometry. Results A significant reduction in plasma methylglyoxal concentrations was observed during a 4-week sup plementation period. This reduction suggests a po tential benefit in terms of reducing the formation of harmful AGEs, which could be attributed to the anti oxidant properties of the active compounds in the supplement. The observed reduction in methylgly oxal was around 9.8%, which could be of clinical rele vance in preventing or managing age-related condi tions related to AGEs formation, like cardiovascular related diseases, diabetes and neurodegeneration. This confirms the importance of exploring promis ing nutraceuticals like Actiful® as potential healthy ageing strategies to mitigate the impact of reactive α-dicarbonyl compounds on health.
Conclusion
This study demonstrates the great potential of Actiful® for playing a role in healthy ageing. This is in dicated by the significant reduction in AGEs, specifi cally MGO, found in the present study. Read the complete publication: https://www.mdpi.com/1422-0067/24/17/13168
13
